Inhibition of antigen presentation during AAV gene therapy using virus peptides.

about

Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy

P2860

Q57039821-F0B8D538-9A2A-43BF-9B5E-C995F271BC8D

P2860

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

Item

http://www.wikidata.org/entity/Q47260510

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

@en

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

@nl

type

Item

label

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

@en

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

@nl

prefLabel

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

@en

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

@nl

P1476

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

@en

P2093

Chengwen Li

http://www.w3.org/2001/XMLSchema#string

Matthew L Hirsch

http://www.w3.org/2001/XMLSchema#string

R Jude Samulski

http://www.w3.org/2001/XMLSchema#string

Wenwei Shao

http://www.w3.org/2001/XMLSchema#string

Xiaojing Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus

Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47

Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines

The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice

Cytomegaloviral control of MHC class I function in the mouse.

Systemic Trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for duchenne muscular dystrophy

Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability

P31

scholarly article

P356

10.1093/HMG/DDX427

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29272432

http://www.w3.org/2001/XMLSchema#string

P932

5886241

http://www.w3.org/2001/XMLSchema#string

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

about

P2860

P2860

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P932